Clinical Trial Update: Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for BEBT-908 in relapsed or refractory diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• BEBT-908 (BEBT-908)

Snippet

Sponsor: BeBetter Med Inc | Conditions: Relapsed or Refractory Diffuse Large B-cell Lymphoma | Phase 2 | Status: UNKNOWN